Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R

EMBO Journal

Volumn 28, Issue 7, 2009, Pages 866-876

  Sheng, Zhi ^a   Wang, Shu Zong ^a   Green, Michael R ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

24p3; 24p3R; BCRABL; Imatinib mesylate; Ras

Indexed keywords

BCR ABL PROTEIN; CELL SURFACE RECEPTOR; HISTONE DEACETYLASE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; STAT5 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX3; TRANSCRIPTION FACTOR SIN3A; UNCLASSIFIED DRUG; LIPOCALIN; PIPERAZINE DERIVATIVE; PROTEIN P21; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; DOWN REGULATION; FEMALE; GENETICS; METABOLISM; MOUSE MUTANT; MOUSE STRAIN;

ANIMALS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DOWN-REGULATION; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LIPOCALINS; MALE; MICE; MICE, INBRED STRAINS; MICE, SCID; PIPERAZINES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS P21(RAS); PYRIMIDINES; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 65449153532     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/emboj.2009.35     Document Type: Article

References (43)

1. Agarwal A, Eide CA, Harlow A, Corbin AS, Mauro MJ, Druker BJ, Corless CL, Heinrich MC, Deininger MW (2008) An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. Leukemia 22: 2269-2272
2. Ayer DE (1999) Histone deacetylases: transcriptional repression with SINers and NuRDs. Trends Cell Biol 9: 193-198
3. Barbacid M (1987) ras genes. Annu Rev Biochem 56: 779-827
4. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100-104
5. Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY, Weinmann R, Holyoake TL (2008) BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 111: 2843-2853
6. Cross NC, Reiter A (2002) Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 16: 1207-1212
7. Danial NN, Rothman P (2000) JAK-STAT signaling activated by Abl oncogenes. Oncogene 19: 2523-2531
8. Devireddy LR, Gazin C, Zhu X, Green MR (2005) A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 123: 1293-1305
9. Devireddy LR, Teodoro JG, Richard FA, Green MR (2001) Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 293: 829-834
10. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101: 690-698
11. Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M (2004) Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 64: 672-677
12. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632
13. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16: 2190-2196
14. Hoover RR, Mahon FX, Melo JV, Daley GQ (2002) Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 100: 1068-1071
15. Ilaria Jr RL, Van Etten RA (1996) P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271: 31704-31710
16. Kaneta Y, Kagami Y, Tsunoda T, Ohno R, Nakamura Y, Katagiri T (2003) Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray. Int J Oncol 23: 681-691
17. Kantarjian HM, Giles F, Quintas-Cardama A, Cortes J (2007) Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 13: 1089-1097
18. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE, Skorski T (2002) The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 21: 5766-5774
19. Lackey K, Cory M, Davis R, Frye SV, Harris PA, Hunter RN, Jung DK, McDonald OB, McNutt RW, Peel MR, Rutkowske RD, Veal JM, Wood ER (2000) The discovery of potent cRaf1 kinase inhibitors. Bioorg Med Chem Lett 10: 223-226
20. LeMaistre A, Lee MS, Talpaz M, Kantarjian HM, Freireich EJ, Deisseroth AB, Trujillo JM, Stass SA (1989) Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood 73: 889-891
21. Leng X, Lin H, Ding T, Wang Y, Wu Y Klumpp S, Sun T, Zhou Y, Monaco P, Belmont J, Aderem A, Akira S, Strong R, Arlinghaus R (2008) Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene 27: 6110-6119
22. Levanon D, Groner Y (2004) Structure and regulated expression of mammalian RUNX genes. Oncogene 23: 4211-4219
23. Lin F, Monaco G, Sun T, Liu J, Lin H, Stephens C, Belmont J, Arlinghaus RB (2001) BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model. Oncogene 20: 1873-1881
24. Lin H, Monaco G, Sun T, Ling X, Stephens C, Xie S, Belmont J, Arlinghaus R (2005) Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia. Oncogene 24: 3246-3256
25. Lutterbach B, Westendorf JJ, Linggi B, Isaac S, Seto E, Hiebert SW (2000) A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem 275: 651-656
26. Melo JV, Deininger MW (2004) Biology of chronic myelogenous leukemia - signaling pathways of initiation and transformation. Hematol Oncol Clin North Am 18: 545-568, vii-viii
27. Nelson EA, Walker SR, Alvarez JV, Frank DA (2004) Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification. J Biol Chem 279: 54724-54730
28. Park SH, Liu X, Hennighausen L, Davey HW, Waxman DJ (1999) Distinctive roles of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression. Impact of STAT5a gene disruption. J Biol Chem 274: 7421-7430
29. Peggs K, Mackinnon S (2003) Imatinib mesylate - new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 348: 1048-1050
30. Raha T, Cheng SW, Green MR (2005) HIV-1 Tat stimulates transcription complex assembly through recruitment of TBP in the absence of TAFs. PLoS Biol 3: e44
31. Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5: 172-183
32. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J (1997) Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89: 457-467
33. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB (2006) Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 66: 6468-6472
34. Skorski T (2002) Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer 2: 351-360
35. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18: 189-218
36. Tao WJ, Lin H, Sun T, Samanta AK, Arlinghaus R (2008) BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor. Oncogene 27: 3194-3200
37. Taparowsky E, Shimizu K, Goldfarb M, Wigler M (1983) Structure and activation of the human N-ras gene. Cell 34: 581-586
38. Tauchi T, Ohyashiki K (2004) Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia. Int J Hematol 79: 434-440
39. Thompson JE, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, Cunningham BR, Cameron PM, Meinke PT, Liverton N, Weng Y, DeMartino JA (2002) Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett 12: 1219-1223
40. Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248
41. Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, Burchert A (2007) Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 109: 2147-2155
42. White MA, Nicolette C, Minden A, Polverino A, Van Aelst L, Karin M, Wigler MH (1995) Multiple Ras functions can contribute to mammalian cell transformation. Cell 80: 533-541
43. Yan J, Roy S, Apolloni A, Lane A, Hancock JF (1998) Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 273: 24052-24056